RecruitingPhase 2/3

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

United States160 participantsStarted 2026-04-16

Plain-language summary

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion Criteria: * Physician diagnosis of Dry Eye Disease in the past 6 months * Use of over-the-counter tears * Must agree to genotype testing Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.

What they're measuring

Change from baseline in global ocular discomfort severity score at Day 29 in participants with DED and specific TNFR1 genotype

Timeframe: From Day 1 to Day 29

Trial details

NCT IDNCT07548632

SponsorOculis

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Oculis Chief Development Officer

617 928 5886 info@oculis.com

View on ClinicalTrials.gov More Dry Eye Disease (DED) trials